Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGN Allergan	$193.02	$190.89	$114.27 ▼ $202.21	$63.50B	1.2	4.01 million shs	12.44 million shs
BAYRY Bayer Aktiengesellschaft	$8.02 +0.7%	$7.25	$4.79 ▼ $8.58	$31.53B	0.86	764,684 shs	131,090 shs
REGN Regeneron Pharmaceuticals	$546.17 -0.3%	$547.51	$476.49 ▼ $1,211.20	$58.88B	0.33	906,838 shs	210,106 shs
VRTX Vertex Pharmaceuticals	$473.68 +1.6%	$449.35	$377.85 ▼ $519.88	$121.65B	0.41	1.42 million shs	252,900 shs
ZTS Zoetis	$156.56 -0.8%	$161.27	$139.70 ▼ $200.33	$69.69B	0.91	2.57 million shs	835,768 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGN Allergan	0.00%	0.00%	0.00%	0.00%	0.00%
BAYRY Bayer Aktiengesellschaft	+4.32%	+2.05%	+5.01%	+39.09%	+14.02%
REGN Regeneron Pharmaceuticals	+1.79%	+2.40%	+11.06%	-5.02%	-47.94%
VRTX Vertex Pharmaceuticals	+1.51%	+3.14%	+3.52%	-3.30%	-3.22%
ZTS Zoetis	+0.47%	-0.86%	-7.31%	+2.52%	-10.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGN Allergan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BAYRY Bayer Aktiengesellschaft	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	4.9364 of 5 stars	4.4	5.0	1.7	2.3	2.8	1.7	1.9
VRTX Vertex Pharmaceuticals	4.345 of 5 stars	2.3	5.0	0.0	3.3	3.5	2.5	1.3
ZTS Zoetis	4.8228 of 5 stars	3.5	5.0	4.2	0.4	3.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGN Allergan	0.00	N/A	N/A	N/A
BAYRY Bayer Aktiengesellschaft	3.25	Buy	N/A	N/A
REGN Regeneron Pharmaceuticals	2.80	Moderate Buy	$813.57	48.96% Upside
VRTX Vertex Pharmaceuticals	2.54	Moderate Buy	$511.62	8.01% Upside
ZTS Zoetis	3.00	Buy	$212.13	35.49% Upside

Current Analyst Ratings Breakdown

Latest ZTS, BAYRY, REGN, AGN, and VRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	REGN Regeneron Pharmaceuticals	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/23/2025	VRTX Vertex Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$550.00
6/20/2025	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$464.00 ➝ $460.00
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
6/17/2025	VRTX Vertex Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Perform ➝ Sector Perform	$423.00 ➝ $420.00
6/11/2025	BAYRY Bayer Aktiengesellschaft	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/11/2025	BAYRY Bayer Aktiengesellschaft	Kepler Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
6/9/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$950.00 ➝ $800.00
6/5/2025	BAYRY Bayer Aktiengesellschaft	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/5/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$633.00 ➝ $560.00
6/2/2025	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$700.00 ➝ $650.00

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGN Allergan	$16.09B	3.95	$36.70 per share	5.26	$177.28 per share	1.09
BAYRY Bayer Aktiengesellschaft	$50.44B	0.63	$3.97 per share	2.02	$8.82 per share	0.91
REGN Regeneron Pharmaceuticals	$14.20B	4.15	$46.40 per share	11.77	$268.50 per share	2.03
VRTX Vertex Pharmaceuticals	$11.02B	11.04	N/A	N/A	$63.72 per share	7.43
ZTS Zoetis	$9.26B	7.53	$7.05 per share	22.21	$10.57 per share	14.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGN Allergan	-$5.27B	$17.64	N/A	10.65	1.63	-15.44%	8.46%	5.31%	N/A
BAYRY Bayer Aktiengesellschaft	-$2.76B	-$0.92	N/A	7.04	N/A	-7.26%	13.94%	4.09%	8/5/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	13.89	14.37	1.98	31.94%	15.27%	11.93%	8/1/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$3.92	N/A	27.05	N/A	-8.91%	-3.36%	-2.42%	7/30/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	28.10	23.19	2.60	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest ZTS, BAYRY, REGN, AGN, and VRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	N/A	BAYRY Bayer Aktiengesellschaft	$0.23	N/A	N/A	N/A	$10.79 billion	N/A
8/5/2025	Q2 2025	ZTS Zoetis	$1.61	N/A	N/A	N/A	$2.41 billion	N/A
8/1/2025	Q2 2025	REGN Regeneron Pharmaceuticals	$8.53	N/A	N/A	N/A	$3.30 billion	N/A
5/13/2025	Q1 2025	BAYRY Bayer Aktiengesellschaft	$0.63	$0.65	+$0.02	$0.35	$13.39 billion	$15.27 billion
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
5/5/2025	Q1 2025	VRTX Vertex Pharmaceuticals	$4.29	$4.06	-$0.23	$2.49	$2.85 billion	$2.77 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGN Allergan	$2.96	1.53%	N/A	16.78%	N/A
BAYRY Bayer Aktiengesellschaft	$0.02	0.25%	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.64%	N/A	8.96%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZTS Zoetis	$2.00	1.28%	N/A	35.91%	14 Years

Latest ZTS, BAYRY, REGN, AGN, and VRTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025
4/22/2025	BAYRY Bayer Aktiengesellschaft		$0.0224	0.38%	4/29/2025	4/30/2025	5/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGN Allergan	0.31	1.01	0.84
BAYRY Bayer Aktiengesellschaft	1.07	1.25	0.79
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03
VRTX Vertex Pharmaceuticals	0.01	2.65	2.29
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGN Allergan	83.91%
BAYRY Bayer Aktiengesellschaft	N/A
REGN Regeneron Pharmaceuticals	83.31%
VRTX Vertex Pharmaceuticals	90.96%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
AGN Allergan	0.08%
BAYRY Bayer Aktiengesellschaft	N/A
REGN Regeneron Pharmaceuticals	7.02%
VRTX Vertex Pharmaceuticals	0.20%
ZTS Zoetis	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGN Allergan	17,400	329.00 million	N/A	Optionable
BAYRY Bayer Aktiengesellschaft	92,815	3.93 billion	N/A	Not Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable
VRTX Vertex Pharmaceuticals	6,100	256.80 million	256.28 million	Optionable
ZTS Zoetis	13,800	445.21 million	444.50 million	Optionable

ZTS, BAYRY, REGN, AGN, and VRTX Headlines

Recent News About These Companies

Zoetis Inc. (NYSE:ZTS) Stock Position Raised by Bridges Investment Management Inc.

2 hours ago | marketbeat.com

Banque Pictet & Cie SA Purchases 24,546 Shares of Zoetis Inc. (NYSE:ZTS)

2 hours ago | marketbeat.com

Wealth Advisory Solutions LLC Lowers Stock Position in Zoetis Inc. (NYSE:ZTS)

2 hours ago | marketbeat.com

Lbp Am Sa Decreases Stake in Zoetis Inc. (NYSE:ZTS)

2 hours ago | marketbeat.com

Flossbach Von Storch SE Makes New $292,000 Investment in Zoetis Inc. (NYSE:ZTS)

4 hours ago | marketbeat.com

DekaBank Deutsche Girozentrale Buys 37,544 Shares of Zoetis Inc. (NYSE:ZTS)

5 hours ago | marketbeat.com

ZTS - Zoetis Inc Class A Sustainability - Morningstar

July 8 at 1:27 PM | morningstar.comM

ZTS - Zoetis Inc Class A Financials - Morningstar

July 8 at 1:27 PM | morningstar.comM

M&T Bank Corp Has $41.56 Million Stake in Zoetis Inc. (NYSE:ZTS)

July 8 at 9:04 AM | marketbeat.com

Stratos Wealth Partners LTD. Reduces Position in Zoetis Inc. (NYSE:ZTS)

July 8 at 9:03 AM | marketbeat.com

Walter Public Investments Inc. Buys 17,727 Shares of Zoetis Inc. (NYSE:ZTS)

July 8 at 7:38 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Brown Advisory Inc.

July 8 at 7:28 AM | marketbeat.com

Ninety One SA PTY Ltd Sells 1,800 Shares of Zoetis Inc. (NYSE:ZTS)

July 8 at 7:27 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Ninety One UK Ltd

July 8 at 7:07 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Stock Position Raised by Crossmark Global Holdings Inc.

July 8 at 6:42 AM | marketbeat.com

Envestnet Asset Management Inc. Buys 40,380 Shares of Zoetis Inc. (NYSE:ZTS)

July 8 at 5:58 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Receives Average Recommendation of "Buy" from Analysts

July 8 at 2:54 AM | marketbeat.com

Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost

July 7 at 2:52 PM | benzinga.com

SGIOY or ZTS: Which Is the Better Value Stock Right Now?

July 7 at 12:41 PM | zacks.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by Financial Counselors Inc.

July 7 at 7:15 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Purchased by Concurrent Investment Advisors LLC

July 7 at 5:43 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year
By Leo Miller | June 10, 2025
View Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year
The Top Insider Sells From Q2: Buy, Sell, or Hold?
By Thomas Hughes | June 30, 2025
View The Top Insider Sells From Q2: Buy, Sell, or Hold?

ZTS, BAYRY, REGN, AGN, and VRTX Company Descriptions

Allergan NYSE:AGN

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$8.02 +0.05 (+0.66%)

As of 10:57 AM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Regeneron Pharmaceuticals NASDAQ:REGN

$546.16 -1.59 (-0.29%)

As of 11:28 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals NASDAQ:VRTX

$473.68 +7.32 (+1.57%)

As of 11:28 AM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Zoetis NYSE:ZTS

$156.56 -1.24 (-0.79%)

As of 11:28 AM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZTS, BAYRY, REGN, AGN, and VRTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZTS, BAYRY, REGN, AGN, and VRTX Earnings

Compare Dividends

Latest ZTS, BAYRY, REGN, AGN, and VRTX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZTS, BAYRY, REGN, AGN, and VRTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZTS, BAYRY, REGN, AGN, and VRTX Company Descriptions

Allergan NYSE:AGN

Bayer Aktiengesellschaft OTCMKTS:BAYRY

Regeneron Pharmaceuticals NASDAQ:REGN

Vertex Pharmaceuticals NASDAQ:VRTX

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools